Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISMN and frusemide for elevated LVEDP after STEMI
ACTRN12618000096257Phase 2Not yet recruiting
- Sponsor
- The Heart Foundation
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of isosorbide mononitrate and furosemide in myocardial infarction (MI) (2 arms), sponsored by The Heart Foundation. Primary endpoint: Change in left ventricular end diastolic volume index. Planned start Feb 2018; status: not yet recruiting.
02
Drugs
isosorbide mononitratefurosemide
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ACTRN12618000096257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000096257.